Data from the GLASSY trial, an adjudication sub-study of the GLOBAL LEADERS trial, showed that ticagrelor monotherapy after 1 month of dual antiplatelet therapy (DAPT) was non-inferior to conventional DAPT in the prevention of all-cause death, non-fatal myocardial infarction (MI), non-fatal stroke, or urgent target-vessel revascularisation (TVR) at 2 years .
Results from the GLOBAL LEADERS trial showed that ticagrelor with 1 month of aspirin did not reduce the composite of death or Q-wave myocardial infarction compared with 1 year of DAPT followed by aspirin . By design, all clinical endpoints in the GLOBAL LEADERS trial were investigator-reported without central adjudication. The sub-study GLASSY was designed to prospectively implement an independent central adjudication process of both reported events and potentially unreported event triggers to further assess the impact of this novel experimental treatment in a large stratified sample of patients ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Apixaban is safe and effective in real-world setting for treatment of venous thromboembolism Next Article
Clopidogrel monotherapy after 1-month DAPT may be beneficial in stent patients »
Table of Contents: ACC 2019
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Pulmonary Arterial Hypertension and Venous Thromboembolism
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.